關(guān)鍵詞

癌基因 抗體 靶點 單克隆抗體 ?AI?新冠

?

#今日行業(yè)熱點#

①Nature Reviews Clinical Oncology：Rare molecular subtypes of lung cancer

罕見癌基因驅(qū)動的肺癌分子亞型

DOI :10.1038/s41571-023-00733-6

②Nature Cancer：Advances in antibody-based therapy in oncology

綜述：腫瘤學(xué)中基于抗體的治療的進展——新近工程抗體治療候選類別、分子結(jié)構(gòu)和作用機制

DOI :10.1038/s43018-023-00516-z

③Matrix Biology：Targeting LAYN inhibits colorectal cancer metastasis and tumor-associated macrophage infiltration induced by hyaluronan oligosaccharides

靶向LAYN可抑制透明質(zhì)酸寡糖誘導(dǎo)的結(jié)直腸癌轉(zhuǎn)移和腫瘤相關(guān)巨噬細胞浸潤
DOI :10.1016/j.matbio.2023.02.005

④Cancer Immunology Research：Reverse translation identifies the synergistic role of immune checkpoint blockade and IL-15 to enhance immunotherapy of ovarian cancer

PD-1/PD-L1阻斷聯(lián)合IL-15信號通路可能克服卵巢癌對細胞因子治療的耐藥性

DOI :10.1158/2326-6066.CIR-22-0600

⑤Allergy：Hinge region modification for the engineering of antibody function

用于抗體功能工程的鉸鏈區(qū)修飾

DOI :10.1111/all.15684

⑥Kidney International：Identification of proteinase 3 autoreactive CD4+T cells and their T-cell receptor repertoires in anti-neutrophil cytoplasmic antibodies associated vasculitis

PR3-ANCA 相關(guān)性血管炎（PR3-AAV）患者的PR3特異性CD4+T細胞反應(yīng)和自身反應(yīng)性T細胞的特征

DOI :10.1016/j.kint.2023.01.023

⑦靶向補體因子C5的全人源IgG4單克隆抗體靶向藥C5單抗獲美國FDA優(yōu)先審評治療CHAPLE疾病

⑧輝瑞二價呼吸道合胞病毒(RSV)候選疫苗生物制品許可申請獲得FDA的優(yōu)先審查

⑨由Insilico Medicine AI篩選的一款靶向主蛋白酶（3CLpro）的高選擇性小分子抑制劑臨床試驗申請獲批

⑩美國FDA出臺法規(guī)草案：允許植物奶標(biāo)注為“奶”

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！

?